Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.

Abrams T, Connor A, Fanton C, Cohen SB, Huber T, Miller K, Hong EE, Niu X, Kline J, Ison-Dugenny M, Harris S, Walker D, Krauser K, Galimi F, Wang Z, Ghoddusi M, Mansfield K, Lee-Hoeflich ST, Holash J, Pryer N, Kluwe W, Ettenberg SA, Sellers WR, Lees E, Kwon P, Abraham JA, Schleyer SC.

Clin Cancer Res. 2018 Sep 1;24(17):4297-4308. doi: 10.1158/1078-0432.CCR-17-3795. Epub 2018 May 15.

2.

Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.

Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M, Muller K, Bellamacina C, Lindvall MK, Zang R, Huh K, Feucht P, Zavorotinskaya T, Dai Y, Basham S, Chan J, Ginn E, Aycinena A, Holash J, Castillo J, Langowski JL, Wang Y, Chen MY, Lambert A, Fritsch C, Kauffmann A, Pfister E, Vanasse KG, Garcia PD.

J Med Chem. 2015 Nov 12;58(21):8373-86. doi: 10.1021/acs.jmedchem.5b01275. Epub 2015 Oct 27.

PMID:
26505898
3.

The identification and characterization of a STAT5 gene signature in hematologic malignancies.

Sonkin D, Palmer M, Rong X, Horrigan K, Regnier CH, Fanton C, Holash J, Pinzon-Ortiz M, Squires M, Sirulnik A, Radimerski T, Schlegel R, Morrissey M, Cao ZA.

Cancer Biomark. 2015;15(1):79-87. doi: 10.3233/CBM-140434.

PMID:
25524945
4.

A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.

Menezes DL, Holt J, Tang Y, Feng J, Barsanti P, Pan Y, Ghoddusi M, Zhang W, Thomas G, Holash J, Lees E, Taricani L.

Mol Cancer Res. 2015 Jan;13(1):120-9. doi: 10.1158/1541-7786.MCR-14-0240. Epub 2014 Sep 17.

5.

Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.

Burger MT, Han W, Lan J, Nishiguchi G, Bellamacina C, Lindval M, Atallah G, Ding Y, Mathur M, McBride C, Beans EL, Muller K, Tamez V, Zhang Y, Huh K, Feucht P, Zavorotinskaya T, Dai Y, Holash J, Castillo J, Langowski J, Wang Y, Chen MY, Garcia PD.

ACS Med Chem Lett. 2013 Oct 15;4(12):1193-7. doi: 10.1021/ml400307j. eCollection 2013 Dec 12.

6.

Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.

Garcia PD, Langowski JL, Wang Y, Chen M, Castillo J, Fanton C, Ison M, Zavorotinskaya T, Dai Y, Lu J, Niu XH, Basham S, Chan J, Yu J, Doyle M, Feucht P, Warne R, Narberes J, Tsang T, Fritsch C, Kauffmann A, Pfister E, Drueckes P, Trappe J, Wilson C, Han W, Lan J, Nishiguchi G, Lindvall M, Bellamacina C, Aycinena JA, Zang R, Holash J, Burger MT.

Clin Cancer Res. 2014 Apr 1;20(7):1834-45. doi: 10.1158/1078-0432.CCR-13-2062. Epub 2014 Jan 28.

7.

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.

Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, Shannon K, Garcia PD.

Blood. 2013 Aug 29;122(9):1610-20. doi: 10.1182/blood-2013-01-481457. Epub 2013 Jul 1.

8.

Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.

Damiano JS, Rendahl KG, Karim C, Embry MG, Ghoddusi M, Holash J, Fanidi A, Abrams TJ, Abraham JA.

Mol Cancer Ther. 2013 Mar;12(3):295-305. doi: 10.1158/1535-7163.MCT-12-0886. Epub 2012 Dec 27.

9.

Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade.

Huang J, Bae JO, Tsai JP, Kadenhe-Chiweshe A, Papa J, Lee A, Zeng S, Kornfeld ZN, Ullner P, Zaghloul N, Ioffe E, Nandor S, Burova E, Holash J, Thurston G, Rudge J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.

Int J Oncol. 2009 Jan;34(1):79-87.

10.

VEGF Trap induces antiglioma effect at different stages of disease.

Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK.

Neuro Oncol. 2008 Dec;10(6):940-5. doi: 10.1215/15228517-2008-061. Epub 2008 Aug 14.

11.

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Luqman M, Klabunde S, Lin K, Georgakis GV, Cherukuri A, Holash J, Goldbeck C, Xu X, Kadel EE 3rd, Lee SH, Aukerman SL, Jallal B, Aziz N, Weng WK, Wierda W, O'Brien S, Younes A.

Blood. 2008 Aug 1;112(3):711-20. doi: 10.1182/blood-2007-04-084756. Epub 2008 May 22.

12.

Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation.

Kadenhe-Chiweshe A, Papa J, McCrudden KW, Frischer J, Bae JO, Huang J, Fisher J, Lefkowitch JH, Feirt N, Rudge J, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ.

Mol Cancer Res. 2008 Jan;6(1):1-9. doi: 10.1158/1541-7786.MCR-07-0101.

13.

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.

Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G, Stahl N, Yancopoulos GD.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18363-70. Epub 2007 Nov 13.

14.

VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.

Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, Yancopoulos GD, Dicker AP.

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1526-37. Epub 2007 Jan 17.

PMID:
17234361
15.

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, Jiang S, Nayak NR, Kuypers FA, Ma L, Sundram U, Wu G, Garcia JA, Schrier SL, Maher JJ, Johnson RS, Yancopoulos GD, Mulligan RC, Kuo CJ.

Nat Med. 2006 Jul;12(7):793-800. Epub 2006 Jun 25. Erratum in: Nat Med. 2009 Apr;15(4):462. Niyak, Nihar R [corrected to Nayak, Nihar R].

PMID:
16799557
16.

Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.

Holash J, Thurston G, Rudge JS, Yancopoulos GD, Adjei AA, Bergers G, Pytowski B, Pegram M, Gordon MS.

Cancer Metastasis Rev. 2006 Jun;25(2):243-52. Review. No abstract available.

PMID:
16770536
17.

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.

Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-71.

18.

Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development.

Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G, Yancopoulos GD.

Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15949-54. Epub 2004 Nov 1.

19.

Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.

Frischer JS, Huang J, Serur A, Kadenhe-Chiweshe A, McCrudden KW, O'Toole K, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.

Int J Oncol. 2004 Sep;25(3):549-53.

PMID:
15289855
20.

TNP-470 promotes initial vascular sprouting in xenograft tumors.

Huang J, Frischer JS, New T, Kim ES, Serur A, Lee A, Kadenhe-Chiwishe A, Pollyea DA, Yokoi A, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ.

Mol Cancer Ther. 2004 Mar;3(3):335-43.

21.

The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis.

Saucier C, Khoury H, Lai KM, Peschard P, Dankort D, Naujokas MA, Holash J, Yancopoulos GD, Muller WJ, Pawson T, Park M.

Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2345-50.

22.

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.

Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB.

Clin Cancer Res. 2003 Nov 15;9(15):5721-8.

23.

Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation.

Gale NW, Thurston G, Davis S, Wiegand SJ, Holash J, Rudge JS, Yancopoulos GD.

Cold Spring Harb Symp Quant Biol. 2002;67:267-73. No abstract available.

PMID:
12858549
24.

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.

Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7785-90. Epub 2003 Jun 12.

25.

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ.

Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11399-404. Epub 2002 Aug 12.

26.

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS.

Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8. Epub 2002 Aug 12.

27.

Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome.

Wong AK, Alfert M, Castrillon DH, Shen Q, Holash J, Yancopoulos GD, Chin L.

Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7481-6. Epub 2001 Jun 12.

28.

Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells.

Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, McDonald DM, Yancopoulos GD.

Dev Biol. 2001 Feb 15;230(2):151-60.

29.

Molecular events implicated in brain tumor angiogenesis and invasion.

Zagzag D, Friedlander DR, Margolis B, Grumet M, Semenza GL, Zhong H, Simons JW, Holash J, Wiegand SJ, Yancopoulos GD.

Pediatr Neurosurg. 2000 Jul;33(1):49-55. Review.

PMID:
11025423
30.

Vascular-specific growth factors and blood vessel formation.

Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J.

Nature. 2000 Sep 14;407(6801):242-8. Review.

PMID:
11001067
31.

Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis.

Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, Zabski S, Yancopoulos GD, Grumet M.

Lab Invest. 2000 Jun;80(6):837-49.

32.

Angiopoietin-1 protects the adult vasculature against plasma leakage.

Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD.

Nat Med. 2000 Apr;6(4):460-3.

PMID:
10742156
33.

In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis.

Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos GD, Grumet M.

Exp Neurol. 1999 Oct;159(2):391-400.

PMID:
10506510
34.
35.

Essential role for oncogenic Ras in tumour maintenance.

Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA.

Nature. 1999 Jul 29;400(6743):468-72.

PMID:
10440378
36.

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ.

Science. 1999 Jun 18;284(5422):1994-8.

37.

Immunolocalization of the receptor tyrosine kinase EphA4 in the adult rat central nervous system.

Martone ME, Holash JA, Bayardo A, Pasquale EB, Ellisman MH.

Brain Res. 1997 Oct 17;771(2):238-50.

PMID:
9401744
38.

Reciprocal expression of the Eph receptor Cek5 and its ligand(s) in the early retina.

Holash JA, Soans C, Chong LD, Shao H, Dixit VM, Pasquale EB.

Dev Biol. 1997 Feb 15;182(2):256-69.

39.
40.

B61, a ligand for the Eck receptor protein-tyrosine kinase, exhibits neurotrophic activity in cultures of rat spinal cord neurons.

Magal E, Holash JA, Toso RJ, Chang D, Lindberg RA, Pasquale EB.

J Neurosci Res. 1996 Mar 15;43(6):735-44.

PMID:
8984203
41.
42.
43.
44.

Barrier properties of testis microvessels.

Holash JA, Harik SI, Perry G, Stewart PA.

Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11069-73.

45.

Re-evaluating the role of astrocytes in blood-brain barrier induction.

Holash JA, Noden DM, Stewart PA.

Dev Dyn. 1993 May;197(1):14-25.

46.

Chorioallantoic membrane (CAM) vessels do not respond to blood-brain barrier (BBB) induction.

Holash JA, Stewart PA.

Adv Exp Med Biol. 1993;331:223-8. No abstract available.

PMID:
8333337
47.

The difference in vascular volume between cerebrum and cerebellum is in the pia mater.

Holash JA, Sugamori K, Stewart PA.

J Cereb Blood Flow Metab. 1990 May;10(3):432-4.

PMID:
2329130
48.

Effect of bile duct ligation-induced liver damage on the blood-brain barrier.

Stewart PA, Farrell CR, Holash JA, Elliot D, Neiman J, Resch L, Carlen PL.

Can J Neurol Sci. 1989 Nov;16(4):451-2. No abstract available.

PMID:
2804810

Supplemental Content

Loading ...
Support Center